Anika Therapeutics, Inc. (ANIK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	120.7M	112.8M	119.9M	120.8M	113.8M
Cost of Revenue	45.6M	49.0M	43.9M	38.3M	40.6M
Gross Profit	75.0M	63.8M	76.0M	82.5M	73.2M
Operating Expenses
R&D Expense	27.5M	25.8M	25.5M	21.8M	18.3M
SG&A Expense	52.7M	49.1M	55.6M	59.9M	51.2M
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	80.1M	74.9M	81.1M	81.7M	69.5M
Cost and Expenses	125.8M	123.9M	125.0M	119.9M	110.2M
Operating Income (EBIT)	(5.1M)	(11.1M)	(5.1M)	844.0K	3.7M
Non-Operating
Interest Income	426.0K	—	—	2.3M	654.0K
Interest Expense	—	—	—	—	—
Net Interest Income	426.0K	—	—	2.3M	654.0K
Other Non-Op Income/Expense	2.2M	1.7M	2.3M	2.3M	654.0K
Non-Operating Income (excl Interest)	(2.2M)	(1.7M)	(2.3M)	(2.3M)	(654.0K)
EBT (Pre-Tax Income)	(2.9M)	(9.3M)	(2.8M)	3.2M	4.3M
Income Tax Expense	208.0K	672.0K	6.1M	6.6M	2.1M
Bottom Line
Net Income	(3.8M)	(10.9M)	(56.4M)	(82.7M)	(14.9M)
Earnings from Cont. Ops	(3.1M)	(10.0M)	(8.8M)	(3.4M)	2.2M
Earnings from Discont. Ops	(663.0K)	(901.0K)	(47.6M)	(79.2M)	(17.1M)
Bottom Line Net Income	(3.8M)	(10.9M)	(56.4M)	(82.7M)	(14.9M)
Per Share
Basic EPS	($0.27)	($0.76)	($3.83)	($5.64)	($1.02)
Diluted EPS	($0.27)	($0.76)	($3.83)	($5.64)	($1.02)
Revenue Per Share	$8.98	$7.87	$8.15	$8.24	$7.82
Shares
Basic Shares Outstanding	13.4M	14.3M	14.7M	14.7M	14.6M
Diluted Shares Outstanding	13.4M	14.3M	14.7M	14.7M	14.6M
Profitability Metrics
EBITDA	2.7M	(3.6M)	5.4M	17.4M	18.8M
D&A	5.6M	5.7M	8.1M	14.2M	14.5M
EBIT	(2.9M)	(9.3M)	(2.8M)	3.2M	4.3M

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026